Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous tumor infiltrating lymphocytes - Essen Biotech

Next Previous
X
Search
Drug Profile

Autologous tumor infiltrating lymphocytes - Essen Biotech

Alternative Names: TIL therapy - Essen Biotech

Latest Information Update: 04 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Essen BioTech
  • Class Antineoplastics; Immunotherapies; Tumour infiltrating lymphocyte therapies
  • Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Lung cancer

Most Recent Events

  • 20 Aug 2024 Phase-I/II clinical trials in Lung cancer (Late-stage disease, Metastatic disease, In adolescents, In adults, In the elderly, Combination therapy) in China (IV) (NCT06538012)
  • 01 Aug 2024 Preclinical trials in Solid tumours in China (IV) prior to August 2024 (NCT06530303)
  • 01 Aug 2024 Essen Biotech plans a phase I/II BAH249 trial for Breast cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater, Combination therapy) in China (IV) (NCT06532812)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top